Relevance of the neuropeptide Y system in the biology of cancer progression

Current Topics in Medicinal Chemistry

Volumn 7, Issue 17, 2007, Pages 1682-1691

  Ruscica, M ^a   Dozio, E ^a   Motta, M ^a   Magni, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Breast cancer; Cell proliferation; Metastatization; Neural crest derived tumors; Neuropeptide Y; Neuropeptide Y receptors; Pancreatic cancer; Peptide YY; Prostate cancer

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; 2 [1 (3 CHLORO 5 ISOPROPOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 2 THIAZOLYL)ETHYL] 4 MORPHOLINOPYRIDINE; ANTINEOPLASTIC AGENT; CP 671906; FMS 56; J 104870; L 152804; LY 357897; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y [DEXTRO 25 ARGININE]; NEUROPEPTIDE Y [DEXTRO 26 HISTIDINE]; NEUROPEPTIDE Y [DEXTRO 32 TRYPTAMINE]; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR AGONIST; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR AGONIST; NEUROPEPTIDE Y2 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y4 RECEPTOR AGONIST; NEUROPEPTIDE Y4 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR AGONIST; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; PEPTIDE YY; PEPTIDE YY (25-36); TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; DRUG STRUCTURE; EWING SARCOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PHEOCHROMOCYTOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CELL GROWTH PROCESSES; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPEPTIDE Y;

EID: 36249013257     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607782341019     Document Type: Review

References (112)

1. Larhammar, D.; Salaneck, E. Molecular evolution of NPY receptor subtypes. Neuropeptides, 2004, 38, 141-151.
2. Schwartz, T. W.; Fuhlendorff, J.; Kjems, L. L.; Kristensen, M. S.; Vervelde, M.; O'Hare, M.; Krstenansky, J. L.; Bjornholm, B. Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann. N. Y. Acad. Sci., 1990, 611, 35-47.
3. Cerda-Reverter, J.; Larhammar, D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem. Cell Biol., 2000, 78, 371-392.
4. Chronwall, B. M. Anatomy and physiology of the neuroendocrine arcuate nucleus. Peptides, 1985, 6 (Suppi 2), 1-11.
5. Cavadas, C.; Ribeiro, C. A.; Cotrim, M.; Mosimann, F.; Brunner, H. R.; Grouzmann, E. Gatecholamine and neuropeptide Y secretion from human adrenal chromaffin cells: effect of nicotine and KC1. Ann. N. Y. Acad. Sci., 2002, 971, 332-334.
6. Berglund, M. M.; Schober, D. A.; Esterman, M. A.; Gehlert, D. R. Neuropeptide Y Y4 receptor homodimers dissociate upon agonist stimulation. J. Pharmacol. Exp. Ther., 2003, 307, 1120-1126.
7. Magni, P. Hormonal control of the neuropeptide Y system. Curr. Protein Pept. Sci., 2003, 4, 45-57.
8. Pedrazzini, T.; Pralong, F., Grouzmann, E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci., 2003, 60, 350-377.
9. Ogasawara, M.; Murata, J.; Ayukawa, K.; Saimi, I. Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer. Lett., 1997, 116, 111-116.
10. Zukowska-Grojec, Z.; Karwatowska-Prokopczuk, E.; Rose, W.; RoNe, J.; Movafagh, S.; Ji, H.; Yeh, Y.; Chen, W. T.; Kleinman, H. K.; Grouzmann, E.; Grant, D. S. Neuropeptide Y: a novel angiogenic factuc from the sympathetic nerves and endothelium. Circ. Res., 1998, 83, 187-195.
11. Movafagh, S.; Hobson, J. P.; Spiegel, S.; Kleinman, H. K.; Zukowska, Z. Neuropeptide Y induces migratign, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J., 2006, 20, 1924-1926.
12. Koglin, N.; Beck-Sickinger, A. G. Novel modified and radio-labelled neuropeptide Y analogues to study Y-receptors subtypes. Neuropeptides, 2004, 38, 153-161.
13. Blomqvist, A. G.; Herzog, H. Y-receptor, subtypes-how many more? Trends Neurosci., 1997, 20, 294-298.
14. Larhammar, D.; Blomqvist, A. G.; Yee, F.; Jazin, E.; You, H.; Wahlestedt, C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol. Chem., 1992, 267, 10935-10938.
15. Mullins, D. E.; Zhang, X.; Hawes, B. E. Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul. Pept., 2002, 105, 65-73.
16. Herzog, H.; Hort, Y. J.; Ball, H. J.; Hayes, G.; Shine, J.; Selbie, L. A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA, 1992, 89, 5794-5798.
17. Gerald, C.; Walker, M. W.; Vaysse, P. J.; He, C.; Branchek, T. A.; Weinshank, R. L. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol. Chem., 1995, 270, 26758-26761.
18. Robidoux, J.; Simoneau, L.; St-Pierre, S.; Masse, A.; Lafond, J. Characterization of neuropeptide Y-mediated corticotropin-releasing factor synthesis and release from human placental trophoblasts. Endocrinology, 2000, 141, 2795-2804.
19. Hansel, D. E.; Eipper, B. A.; Ronnett, G. V. Neuropeptide Y functions as a neuroproliferative factor. Nature, 2001, 410, 940-944.
20. Cho, Y. R.; Kim, C. W. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem. Biophys. Res. Commun., 2004, 314, 773-780.
21. Ruscica, M.; Dozio, E.; Boghossian, S.; Bovo, G.; Martos Riano, V.; Motta, M.; Magni, P. Activation of the Y1 receptor by neuropeptide y regulates the growth of prostate cancer cells. Endocrinology, 2006, 147, 1466-1473.
22. Wahlestedt, C.; Hakanson, R. Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre- and postjunctional receptors be distinguished? Med. Biol., 1986, 64, 85-88.
23. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature, 1996, 382, 168-171.
24. Mannon, P. J. Peptide YY as a growth factor for intestinal epithelium. Peptides, 2002, 23, 383-388.
25. Liu, C. D.; Balasubramaniam, A.; Saxton, R. E.; Paiva, M.; McFadden, D. W. Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1. J. Surg. Res., 1995, 58, 707-712.
26. Liu, C. D.; Hines, O. J.; Whang, E. E.; Laird, E. C.; Skotzko, M. J.; Zinner, M. J.; Ashley, S. W.; McFadden, D. W. Pancreatic peptide YY mRNA levels increase during adaptation after small intestinal resection. J. Surg. Res., 1995, 58, 6-11.
27. Grise, K. R.; Rongione, A. J.; Laird, E. C.; McFadden, D. W. Peptide YY inhibits growth of human breast cancer in vitro and in vivo. J. Surg. Res., 1999, 82, 151-155.
28. Tatemoto, K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc. Natl. Acad. Sci. USA, 1982, 79, 2514-2518.
29. Lundberg, J. M.; Tatemoto, K.; Terenius, L.; Hellstrom, P. M.; Mutt, V.; Hokfelt, T.; Hamberger, B. Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc. Natl. Acad. Sci USA, 1982, 79, 4471-4475.
30. Hazelwood, R. L. The pancreatic polypeptide (PP-fold) family gastrointestinal, vascular, and feeding behavioral implications. Proc. Soc. Exp. Biol. Med., 1993, 202, 44-63
31. Taylor, I. L. Role of peptide YY in the endocrine control of digestion. J. Dairy Sci., 1993, 76, 2094-2101.
32. Nieuwenhuizen, A. G.; Karlsson, S.; Fridolf, T.; Ahren, B. Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. Diabetologia, 1994, 37, 871-878.
33. Erlinge, D.; Brunkwall, J.; Edvinsson, L. Neuropeptide Y stimulaies proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul. Pept., 1994, 50, 259-265
34. Zukowska, Z.; Grant, D. S.; Lee, E. W. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc. Med., 2003, 13, 86-92.
35. Canto Soler, M. V.; Gallo, J. E.; Dodds, R. A.; Hokfelt, T.; Villar, M. J.; Suburo, A. M. Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina. Glia, 2002, 39, 320-324.
36. Oben, J. A.; Yang, S.; Lin, H.; Ono, M.; Diehl, A. M. Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem. Biophys. Res. Commun., 2003, 302, 685-690.
37. Kitlinska, J.; Abe, K.; Kuo, L.; Pons, J.; Yu, M.; Li, L.; Tilan, J.; Everhart, L.; Lee, E. W.; Zukowska, Z.; Toretsky, J. A. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res., 2005, 65, 1719-1728.
38. Mannon, P. J.; Mele, J. M. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J., 2000, 350 (Pt 3), 655-661.
39. Liu, C. D.; Rongione, A. J.; Garvey, L.; Balasubramaniam, A.; McFadden, D. W. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Am. J. Surg., 1996, 171, 192-196.
40. Kling, K.; Kim, F.; Cole, M.; McFadden, D. B-cell leukemia protein-2 and peptide YY chemotherapy resistance in colon cancer. Am. J. Surg., 1999, 178, 411-414.
41. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.
42. Tuxhorn, J. A.; Ayala, G. E.; Rowley, D. R. Reactive stroma in prostate cancer progression. J. Urol., 2001, 166, 2472-2483.
43. van Moorselaar, R. J.; Voest, E. E. Angiogenesis, in prostate cancer: its role in disease progression and possible therapeutic approaches Mol. Cell. Endocrinol., 2002, 197, 239-250.
44. Lee, E. W.; Grant, D. S.; Movafagh, S.; Zukowska, Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides, 2003, 24, 99-106.
45. Tanaka, T.; Kameoka, J.; Yaron, A.; Schlossman, S. F.; Morimoto, C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA, 1993, 90, 4586-4590.
46. Anderson, R. L.; Morris, J. L.; Gibbins, I. L. Neurochemical differentiation of functionally distinct populations of autonomic neurons. J. Comp. Neurol., 2001, 429, 419-435.
47. Smialowska, M.; Obuchowicz, E.; Turchan, J.; Herman, Z. S.; Przewlocki, R. Clonidine administration increases neuropeptide Y immunoreactivity and neuropeptide Y mRNA in the rat cerebral cortex neurons. Neuropeptides, 1997, 31, 203-207.
48. Kitlinska, J.; Lee, E. W.; Movafagh, S.; Pons, J.; Zukowska, Z. Neuropeptide Y-induced angiogenesis in aging. Peptides, 2002, 23, 71-77.
49. Ekstrand, A. J.; Cao, R.; Bjorndahl, M.; Nystrom, S.; Jonsson-Rylander, A. C.; Hassani, H.; Hallberg, B.; Nordlander, M.; Cao, Y. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl. Acad. Sci. USA, 2003, 100, 6033 -6038.
50. Koulu, M.; Movafagh, S.; Tuohimaa, J.; Jaakkola, U.; Kallio, J.; Pesonen, U.; Geng, Y.; Karvonen, M. K.; Vainio-Jylha, E.; Pollonen, M.; Kaipio-Salmi, K.; Seppala, H.; Lee, E. W.; Higgins, R. D.; Zukowska, Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann. Med., 2004, 36, 232-240.
51. Liotta, L. A. Tumor invasion and metastases-role of the extra-cellular matrix: Rhoads Memorial Award lecture. Cancer Res., 1986, 46, 1-7.
52. Terranova,. V. P.; Hujanen, E. S.; Martin, G. R. Basement membrane and the invasive activity of metastatic tumor cells. J. Natl. Cancer Inst., 1986, 77, 311-316.
53. Jarrard, D. F.; Blitz, B. F.; Smith, R. C.; Patai, B. Rukstalis, D. B. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate, 1994, 24, 46-53.
54. Leek, R. D.; Harris, A. L.; Lewis, C. E. Cytokine networks in solid human tumors: regulation of angiogenesis. J. Leukoc. Biol., 1994, 56, 423-435.
55. Stracke, M. L.; Murata, J.; Aznavoorian, S.; Liotta, L. A. The role of the extracellular matrix in tumor cell metastasis. In Vivo, 1994, 8, 49-58.
56. Nagakawa, O.; Ogasawara, M.; Murata, J.; Fuse, H.; Saiki, I. Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int. J. Urol., 2001, 8, 65-70.
57. Nagakawa, O.; Ogasawara, M.; Fujii, H.; Murakami, K.; Murata, J.; fuse, H.; Saiki, I. Effect of prostatic neuropeptides on invasion and migrition of PC-3 prostate cancer cells. Cancer Lett., 1998, 133, 27-33.
58. Kogner, P.; Bjork, O.; Theodorsson, E. Plasma neuropeptide Y in healthy children: influence of age, anaesthesia, and the establishment of an age-adjusted reference interval. Acta Paediatr., 1994, 83, 423-427.
59. Allen, J. M.; Yeats, J. C.; Causon, R.; Brown, M. J.; Bloom, S. R. Neuropeptide Y and its flanking peptide in human endocrine tumors and plasma. J. Clin. Endocrinol. Metab., 1987, 64, 1199-1204.
60. Rascher, W.; Kremens, B.; Wagner, S.; Feth, F.; Hunneman, D. H.; Lang, R. E. Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children. J. Pediatr., 1993, 122, 914-916.
61. Dotsch, J.; Christiansen, H.; Hanze, J.; Lampert, F.; Rascher, W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul. Pept., 1998, 75-76, 185-190.
62. Korner, M.; Waser, B.; Reubi, J. C. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin. Cancer Res., 2004, 10, 8426-8433.
63. Kitlinska, J. Neuropeptide Y in neural crest-derived tumors: Effect on growth and vascularization. Cancer Lett. 2006.
64. Magni, P.; Maggi, R.; Pimpinelli, F.; Motta, M. Cholinergic muscarinic mechanisms regulate neuropeptide Y gene expression via protein kinase C in human neuroblastorna cells. Brain Res., 1998, 798, 75-82.
65. Magni, P.; Beretta, E.; Scaccianoce, E.; Motta, M. Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells. Neuropharmacology, 2000, 39, 1627-1635.
66. Magni, P.; Vettor, R.; Pagano, C.; Calcagno, A.; Martini, L.; Motta, M. Control of the expression of human neuropeptide Y by leptin: in vitro studies. Peptides, 2001, 22, 415-420.
67. Finklestein, J. Z.; Krailo, M. D.; Lenarsky, C.; Ladisch, S.; Blair, J.; Reynolds, C. P.; Sitarz, A. L.; Denmann-Hammon, G. 13-cis retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from Children's Cancer Study Group. Med. Pediat. Oncol., 1992, 20, 307-311
68. Rodriguez-Galindo, C.; Spunt, S. L.; Pappo, A. S. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med. Pediatr. Oncol., 2003, 40, 276-287.
69. Reubi, J. C.; Gugger, M.; Waser, B.; Schaer, J. C. Y1-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets. Cancer Res., 2001, 61, 4636-4641.
70. Kitlinska, J.; Kuo, L.; Abe, K.; Pons, J.; Yu, M.; Li, L.; Tilan, J.; Toretsky, J.; Zukowska, Z. Role of neuropeptide Y and dipeptidyl peptidase IV in regulation of Ewing's sarcoma growth. Adv. Exp. Med. Biol., 2006, 575, 223-229.
71. DiMaggio, D. A.; Farah, J. M., Jr.; Westfall, T. C. Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells. Endocrinology, 1994, 134, 719-727.
72. Bournat, I. C.; Allen, J. M. Regulation of Y1 neuropeptide Y receptor gene expression in PC12 cells. Brain Res. Mol. Brain Res., 2001, 90, 149-164.
73. deS Senanayake, P.; Denker, J.; Bravo, E. L.; Graham, R. M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J. Clin. Invest., 1995, 96, 2503-2509.
74. Liu, J.; Kahri, A. I.; Heikkila, P.; Voutilainen, R. Regulation of neuropeptide Y mRNA expression in cultured human pheochromocytoma cells. Eur. J. Endocrinol., 1999, 141, 431-435.
75. Ganz, P. A. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am. J. Med., 2005, 118, 136-141.
76. Moody, T. W.; Leyton, J.; Gozes, I.; Lang, L.; Eckelman, W. C. VIP and breast cancer. Ann. N. Y. Acad. Sci., 1998, 865, 290-296.
77. Gugger, M.; Reubi, J. C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol., 1999, 155, 2067-2076.
78. Reubi, J. C.; Waser, B.; Schaer, J. C.; Markwalder, R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab., 1995, 80, 2806-2814.
79. Reubi, J. C.; Gugger, M.; Waser, B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med., 2002, 29, 855-862.
80. Amlal, H.; Faroqui, S.; Balasubramaniam, A.; Sheriff, S. Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res., 2006, 66, 3706-3714.
81. Korner, M.; Waser, B.; Reubi, J. C. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab. Invest., 2004, 84, 71-80.
82. Abrahamsson, P. A. Neuroendocrine cells in tumor growth of the prostate. Endocr. Relat. Can., 1999, 6, 503-519.
83. Rasiah, K. K.; Kench, J. G.; Gardiner-Garden, M.; Biankin, A. V.; Golovsky, D.; Brenner, P. C.; Kooner, R.; O'Neill G, F.; Turner, J. J.; Delprado, W.; Lee, C. S.; Brown, D. A.; Breit, S. N.; Grygiel, J. J.; Horvath, L. G.; Stricker, P. D.; Sutherland, R. L.; Henshall, S. M. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 711-716.
84. Mack, D.; Hacker, G. W.; Hauser-Kronberger, C.; Frick, J.; Dietze, O. Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. Eur. J. Cancer, 1997, 33, 317-318.
85. Magni, P.; Motta, M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann. Oncol., 2001, 12, S27-S29.
86. Yu, A.; Somasundar, P.; Balsubramaniam, A.; Rose, A. T.; Vona-Davis, L.; McFadden, D. W. Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor. J. Surg. Res., 2002, 105, 65-68.
87. Nowicki, M.; Miskowiak, B. Comparison of the cell immunophenotype of metastatic and primary foci in stage IV-S neuroblastoma. Folia Histochem. Cytobiol., 2002, 40, 297-303.
88. Nowicki, M.; Ostalska-Nowicka, D.; Miskowiak, B. Prognostic value of stage IV neuroblastoma metastatic immunophenotype in the bone marrow: preliminary report. J. Clin. Pathol., 2006, 59, 150-152.
89. Skibola, D. R.; Smith, M. T.; Bracci, P, M.; Hubbard, A. E.; Agana, L.; Chi, S.; Holly, E. A. Polyrnorphisms in ghrelin and neuropeptide Y genes are associated with non-Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1251-1256.
90. Walsh, D.; Donnelly, S.; Rybicki, L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer, 2000, 8, 175-179.
91. Plata-Salaman, C. R.; Ilyin, S. E.; Gayle, D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am. J. Physiol., 1998, 275, R566-73.
92. Makarenko, I. G.; Meguid, M. M.; Gatto, L.; Chen, C.; Ramos, E. J.; Goncalves, C. G.; Ugrumov, M. V. Normalization of hypothalamic serotonin (5-HT 1B) receptor and NPY in cancer anorexia after tumor resection: an immunocytochemical study. Neurosci. Lett., 2005, 383, 322-327.
93. Jatoi, A.; Loprinzi, C. L.; Sloan, J. A.; Klee, G. G.; Windschitl, H. E. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer, 2001, 92, 629-633.
94. Goncalves, C. G.; Ramos, E. J.; Romanova, I. V.; Suzuki, S.; Chen, C.; Meguid, M. M. Omega-3 fatty acids improve appetite in cancer anorexia, but tumor resecting restores it. Surgery, 2006, 139, 202-208.
95. Calder, P. C. Dietary modification of inflammation with lipids. Proc. Nutr. Soc., 2002, 61, 345-358.
96. Ramos, E. J.; Suzuki, S.; Meguid, M. M.; Laviano, A.; Sato, T.; Chen, C.; Das, U. Changes in hypothalamic neuropeptide Y and monoaminergic system in tumor-bearing rats: pre- and post-tumor resection and at death. Surgery, 2004, 136, 270-276.
97. Reubi, J. C.; Lamberts, S. J.; Krenning, E. P. Receptor imaging of human diseases using radiolabeled peptides. J. Recept. Signal Transduct. Res., 1995, 15, 379-392.
98. Ehrlich, P. The relationship existing between chemical constitution, distribution, and pharmacological action. The collected papers of Paul Ehrlich; Pergamon, 1956; pp. 596-618.
99. Langer, M.; La Bella, R.; Garcia-Garayoa, E.; Beck-Sickinger, A. G. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug. Chem., 2001, 12, 1028-1034.
100. Froidevaux, S.; Hoppeler, A.; Eberle, A. N.; Meier, A. M.; Hausler, M.; Beglinger, C.; Behe, M.; Powell, P.; Macke, H. R. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-totraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology, 2000, 141, 3304-3312.
101. Lister-James, J.; Moyer, B. R.; Dean, R. T. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q. J. Nucl. Med., 1997, 41, 111-118.
102. Liu, C. D.; Kwan, D.; Simon, N.; McFadden, D. W. Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells. J. Gastrointest. Surg., 2001, 5, 147-152.
103. Nouel, D.; Faure, M. P.; St Pierre, J. A.; Alonso, R.; Quirion, R.; Beaudet, A. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. J. Neurosci., 1997, 17, 1795-1803.
104. Bennett, V. J.; Simmons, M. A. Analysis of fluorescently labeled substance P analogs: binding, imaging and receptor activation. BMC. Chem. Biol., 2001, 1, 1.
105. Veyrat-Durebex, C.; Pomerleau, L.; Langlois, D.; Gaudreau, P. Internalization and trafficking of the human and rat growth hormone-releasing hormone receptor. J. Cell. Physiol., 2005, 203, 335-344.
106. Dumont, Y.; Gaudreau, P.; Mazzuferi, M.; Langlois, D.; Chabot, J. G.; Fournier, A.; Simonato, M.; Quirion, R. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes. Br. J. Pharmacol., 2005, 146, 1069-1081.
107. Soll, R. M.; Dinger, M. C.; Lundell, I.; Larhammer, D.; Beck-Sickinger, A. G. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur. J. Biochem., 2001, 268, 2828-2837.
108. Wessels, B. W.; Meares, C. F. Physical and chemical properties of radionuclide therapy. Semin. Radiat. Oncol., 2000, 10, 115-122.
109. Priebe, W. Anthracycline antibiotics-new analog, methods of delivery and mechanism of action. ACS symposium series, 1995.
110. Langer, M.; Kratz, F.; Rothen-Rutishauser, B.; Wunderli-Allenspach, H.; Beck-Sickinger, A. G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem., 2001, 44, 1341-1348.
111. MacNeil- D.J. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr. Topics Med. Chem., 2007, 17, 1721-1733.
112. Matthews, J. E.; Jansen, M.; Lyerly, D.; Cox, R.; Chen, W. J.; Koller, K. J.; Daniels, A. J. Pharmacological characterization and selectivity of the NPY antagonist GR231118 (1229U91) for different NPY receptors. Regul. Pept., 1997, 72, 113-119.